Novo Nordisk A/S Chief Executive Officer Mike Doustdar may have lost out to Pfizer Inc. in a $10 billion takeover battle for obesity drug developer Metsera Inc. But don’t expect him to give up on dealmaking any time soon as the Danish company seeks to regain lost ground in the booming weight-loss market.

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera , capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk .

Pfizer has clinched a deal worth up to $10bn to buy weight-loss start-up Metsera, capping a dramatic takeover battle after Ozempic maker Novo Nordisk tried to gatecrash its earlier bid. After a week-long bidding war which was prompted by Novo submitting an unsolicited offer for Metsera in late October,

Pfizer Inc. has agreed to buy Metsera Inc. in a $10 billion deal, following a tumultuous bidding war with Novo Nordisk A/S for the weight-loss drug startup.

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Fiona Jones reports.

Metsera is belle of the metabolic ball, the subject of an intense bidding war between drug giants Novo and Pfizer. The big picture: Normally, such a takeover target would sit back and wait for the highest number.

U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer late on Friday,

Pfizer has sealed a $10 billion acquisition of obesity drug developer Metsera, marking a major victory in the rapidly expanding weight-loss drug market. The New York-based pharmaceutical giant outbid Danish rival